Leukotriene B₄ promotes neovascularization and macrophage recruitment in murine wet-type AMD models

Fumiyuki Sasaki,¹ Tomoaki Koga,¹ Mai Ohba,¹ Kazuko Saeki,¹ Toshiaki Okuno,¹ Keijiro Ishikawa,² Takahito Nakama,¹ Shintaro Nakao,² Shigeo Yoshida,² Tatsuro Ishibashi,² Hamid Ahmadieh,³ Mozghan Rezaei Kanavi,⁴ Ali Hafezi-Moghadam,⁵ Josef M. Penninger,⁶ Koh-Hei Sonoda,² and Takehiko Yokomizo¹

¹Department of Biochemistry, Juntendo University School of Medicine, Tokyo, Japan. ²Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ³Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁴Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ⁵Molecular Biomarkers Nano-Imaging Laboratory, Brigham & Women’s Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA. ⁶Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.

Introduction

Age-related macular degeneration (AMD), a progressive chronic disease of the central retina, is associated with aging and is a leading cause of blindness worldwide. Here, we demonstrate that leukotriene B₄ (LTB₄) receptor 1 (BLT1) promotes laser-induced choroidal neovascularization (CNV) in a mouse model for wet-type AMD. CNV was significantly less in BLT1-deficient (BLT1-KO) mice compared with BLT1-WT controls. Expression of several proangiogenic and profibrotic factors was lower in BLT1-KO eyes than in BLT1-WT eyes. LTB₄ production in the eyes was substantially increased in the early phase after laser injury. BLT1 was highly expressed in M2 macrophages in vitro and in vivo, and ocular BLT1⁺ M2 macrophages were increased in the aged eyes after laser injury. Furthermore, M2 macrophages were rapidly attracted by LTB₄ and subsequently produced VEGF-A through BLT1-mediated signaling. Consequently, intravitreal injection of M2 macrophages augmented CNV formation, which was attenuated by BLT1 deficiency. Thus, laser-induced injury to the retina triggered LTB₄ production and attracted M2 macrophages via BLT1, leading to development of CNV. A selective BLT1 antagonist (CP105696) and 3 LTB₄ inhibitors (zileuton, MK-886, and bestatin) reduced CNV in a dose-dependent manner. CP105696 also inhibited the accumulation of BLT1⁺ M2 macrophages in the laser-injured eyes of aged mice. Together, these results indicate that the LTB₄-BLT1 axis is a potentially novel therapeutic target for CNV of wet-type AMD.
expressed by various leukocyte subsets, including granulocytes (neutrophils and eosinophils), monocytes, macrophages, DC, differentiated T cells (Th1, Th2, Th17, and effector CD8+ T cells), mast cells, and osteoclasts (10). As shown by previous reports, the LTB4-BLT1 axis regulates inflammatory and immunological responses such as peritonitis (11), bronchial asthma (12, 13), delayed-type hypersensitivity (14), arthritis (15), atherosclerosis (16, 17), multiple sclerosis (18), psoriasis (19), and obesity-associated insulin resistance (20).

Activated macrophages are roughly classified as classically activated (M1-type) or alternatively activated (M2-type) (21). M1 macrophages are induced by pathogen-associated molecular patterns (e.g., LPS) and inflammatory cytokines (e.g., IFN-γ) and defend against invading microbial pathogens such as bacteria, protozoa, and viruses. Several proteins are used as markers to distinguish M1 and M2 macrophages. Inducible NOS (iNOS) is a representative M1 marker (22–25), and costimulatory molecules (CD80 and CD86) and MHC class II are also useful markers for M1 polarization (26–30). M2 macrophages are regulated by Th2 cytokines (e.g., IL-4 and IL-13), antiinflammatory cytokines (e.g., IL-10 and TGF-β), immune complexes, glucocorticoids, and other factors (31), and they are involved in diverse chronic inflammatory diseases such as parasite infections (32), allergies (33), obesity (34, 35), and the proangiogenic responses that occur in cancer (36) and tissue remodeling and repair (37–39). Mannose receptor (MR, CD206), macrophage galactose N-acetyl-glactosamine specific lectin, (Mgl, CD301), programmed cell death 1 ligand 2 (PD-L2, CD273), and PD-L1 (CD274) are well characterized as the cell surface markers (40–44), and Arginase-1, Fizz1, and Ym1 are known as distinct markers (45–48) for M2 polarization. Recently, we and others reported that M2 macrophages recruited to the injured retina make a critical contribution to the pathogenesis of choroidal neovascularization (CNV) in wet AMD (49–53); however, the molecular mechanisms underlying recruitment of M2 macrophages are poorly understood. Here, we show that BLT1 is mainly expressed by M2 macrophages, which are then recruited to laser-induced retinal lesions and produced VEGF-A– in a BLT1-dependent manner. We also show that LTB4–BLT1 signaling exacerbates CNV in a mouse model of wet AMD by increasing expression of proangiogenic and profibrotic markers. Importantly, we confirm that blockade of LTB4–BLT1 signaling strongly inhibits CNV.

**Results**

**BLT1 deficiency ameliorates progression of CNV in a mouse model of AMD.** Recent reports showed that LTB4–BLT1 signaling promotes several chronic diseases including fibrosis (54), insulin resistance (55), tumorigenesis (56); however, its role in chronic eye diseases has been poorly understood. To examine the pathological role of BLT1 in the eye in vivo, we performed retinal laser photocoagulation to induce wet AMD (57) in BLT1-WT and BLT1-deficient (BLT1-KO) mice (13) of various ages. BLT1-WT mice showed an age-dependent increase in CNV volume (Figure 1A, upper panels). Surprisingly, aging did not affect CNV development in BLT1-KO mice, and the volume of CNV was much smaller in old BLT1-KO mice than in old BLT1-WT mice (Figure 1A, lower panels). The CNV volume in BLT1-WT mice increased in an age-dependent manner (average volume in young mice, 3.1 × 10^5 μm^3; middle-aged mice, 5.4 × 10^5 μm^3; and old mice, 7.2 × 10^5 μm^3); this was not the case in BLT1-KO mice on day 7 after injury (young mice, 2.6 × 10^5 μm^3; middle-aged mice, 2.3 × 10^5 μm^3; and old mice, 3.2 × 10^5 μm^3) (Figure 1B). We also observed that the size of the laser-induced lesion in old BLT1-KO mice was smaller than that in old BLT1-WT mice; however, the overall retinal structure was the same in both groups (Figure 1C). We also confirmed that BLT1-KO mice had smaller lesion areas than those of BLT1-WT mice in aged eyes (average area in young BLT1-WT mice, 3.0 × 10^4 μm^2; BLT1-KO mice, 1.3 × 10^4 μm^2) (Figure 1D). In wet AMD, pathological angiogenesis is critically involved in CNV development and accelerates subretinal fibrosis by increasing various cytokines and chemokines (2, 58, 59). Consistently, expression of mRNA encoding proangiogenic growth factors Vegf, Pdgfb, and Fgf2 in laser-injured BLT1-KO eyes was approximately half as much as in BLT1-WT eyes on day 7 after laser injury in old mice (Figure 2A, upper panels). The amounts of mRNA encoding inflammatory cytokines (Il1b and Tnf), endothelial cell markers (Tek, also known as Tie2, and Vwf), and the profibrotic factors Tgfb1, Pdgfb, and Fgf2 (59) were lower in laser-treated BLT1-KO eyes. However, expression of mRNA encoding the chemokines Ccl3 (Figure 2A, middle and lower panels) and Ccl2 (data not shown), both of which were reported to play a role in AMD pathogenesis (60, 61), was not significantly different between the BLT1-KO and BLT-WT groups. We previously cloned a low-affinity LTB4 receptor, BLT2 (62, 63), which is involved in colitis (64), epidermal wound healing (65), and acute lung injury (66), and we examined the effect of BLT2 deficiency in the same AMD model (Supplemental Figure 2). We found that BLT2 was not involved in AMD because the CNV volume in BLT2-KO mice was comparable with that in...
their WT (BLT2-WT) littermates (BLT2-WT mice, $4.4 \times 10^5 \mu m^3$; BLT2-KO mice, $3.4 \times 10^5 \mu m^3$) (Supplementary Figure 2B). Next, we performed the simultaneous quantification of 52 eicosanoids in laser-injured mouse eyes using a liquid chromatography–mass spectrometry (LC-MS/MS) (Figure 2 and Supplementary Figure 3). On days 1 and 3 after laser injury, the amount of LTB$_4$ (Figure 2B) and 5-hydroxyeicosatetraenoic acid (5-HETE) (Supplemental Figure 3A) in the eyes markedly increased both in young and old mice. These results are consistent with the previous studies showing that various leukotrienes, including LTB$_4$, were produced from the retinal glial cells, retinal endothelial cells, and RPE in the pathogenesis of inflammatory eye diseases at early phase (67, 68). Taken together, these results suggest that LTB$_4$-BLT1 signaling is critical for progression of laser-induced CNV.

**BLT1 is expressed by macrophages and is involved in CNV development.** As BLT1 is highly expressed in various subsets of leukocytes, we speculated that BLT1 expressed in retinal leukocytes is responsible for CNV. Previous studies showed that retinal leukocytes were reconstituted with donor leukocytes by BM transplantation (69–73). To examine whether BLT1-expressing leukocytes play a role in laser-induced CNV, we implanted BLT1-WT or BLT1-KO BM cells from aging donors into lethally irradiated WT mice from aging recipients to generate BM chimeric mice and then examined CNV volume (Figure 3, A and B). We confirmed that more than 90% of BM cells and peripheral blood leukocytes (PBL) of the CD45.2 $^+$ recipients (C57BL/6J-Ly5.2 mice) were donor-derived CD45.1 $^+$ cells from a congenic strain (C57BL/6-Ly5.1 mice) (Supplemental Figure 1). Images of isolectin B4 (iB4) staining (A) and CNV volume (B) in the RPE-choroid complex from the eyes of BLT1-WT (open circles) and BLT1-KO (filled circles) mice after laser-induced injury. Green represents a CNV area positive for iB4 staining. Mice were grouped by age: young, 8–12 weeks old; middle-aged, 20–24 weeks old; old, 40–48 weeks old. n = 5–6 mice per group. (C and D) Images of H&E staining (C) and CNV lesion area (D). H&E staining of the uninjured and laser-injured retinas from aged BLT1-WT and BLT1-KO mice (>40 weeks old). Yellow dotted lines denote the lesion areas. n = 4–5 per group. Scale bar: 100 $\mu$m (A and C). (B and D) *P < 0.05; **P < 0.01 (1-way ANOVA with Bonferroni’s post hoc test [B] and Student’s t test [D]). Results are representative of at least 2 independent experiments.
These results showed that the efficiency of BM transplantation is independent of the age of donors or recipients (Supplemental Figure 4, C and D). The volume of CNV in BLT1-KO chimeras (BLT1-WT BM into WT, 10.3 × 10⁵ μm³; BLT1-KO BM into WT, 6.8 × 10⁵ μm³) (Figure 3B). We further analyzed the numbers and the percentages of leukocyte populations in the eyes by FACS analysis (Figure 3, C and D). CD45⁺ total leukocytes and CD11b⁺F4/80⁻Ly6G⁺ neutrophils peaked at day 1, but CD11b⁺F4/80⁻Ly6C⁺ inflammatory monocytes and CD11b⁺F4/80⁺ macrophages peaked at day 3 after laser injury in the eyes of aged WT mice. Consistent with the previous studies, we found that BLT1 is abundantly expressed in CD11b⁺F4/80⁻Ly6G⁺ neutrophils and CD11b⁺F4/80⁺ macrophages in the laser-injured eyes (data not shown). We further observed that BLT1⁺ macrophages infiltrated the periphery of the laser-injured area in the RPE-choroid in aged mice on day 5 after laser injury (Figure 3E, upper panels) but not in young mice (Figure 3E, lower panels). To determine whether BLT1⁺ macrophages contribute to the development of CNV, we next depleted macrophages by IVI of clodronate liposomes (Figure 4 and Supplemental Figure 5) as previously described (74). IVI of clodronate liposomes significantly reduced F4/80⁺ macrophages in the RPE-choroid compared with control liposomes (Supplemental Figure 5C) but did not affect the number of DAPI⁺ cells (Supplemental Figure 5D). Macrophage depletion reduced CNV volume in BLT1-WT mice (control, 13.5 × 10⁵ μm³; clodronate, 2.6 × 10⁵ μm³) to levels observed in BLT1-KO mice (control, 2.5 × 10⁵ μm³; clodronate, 1.1 × 10⁵ μm³) (Figure 4B). Taken together, these results suggest that BLT1⁺ macrophages exacerbate laser-induced CNV.

**BLT1 is expressed in M2 macrophages in vitro and in vivo.** Recent studies have been shown that macrophages are skewed toward proangiogenic phenotype in the injured tissue or the tumor microenvironment (36, 39, 44, 48, 53, 75). Next, we examined BLT1 expression in M1 and M2 macrophages using BM-derived macrophages (BMDMs) (Figure 5, A and B, and Supplemental Figure 6A), RAW264.7 cells (mouse monocyte/macrophage cell line) (Figure 5C), and THP-1 cells (human monocytic cell line) (Figure 5D). M2 polarization of BMDMs induced BLT1 mRNA (Ltb4r1) (Figure 5A and Supplemental Figure 6A, M2) and protein (Figure 5B, M2) expression, while M1 polarization or nonpolarized M0 BMDMs showed lower levels of
Figure 3. BLT1-expressing macrophages are recruited to the periphery of laser-induced CNV. Images of iB4 staining (A) and CNV volume (B) in the RPE-choroid of chimeric mice receiving BM cells from aged BLT1-WT (white) or BLT1-KO (black) mice (>20 weeks old). n = 6–8 mice per group. (C and D) Flow cytometry analysis of cells isolated from the laser-injured eyes of aged WT mice (>20 weeks old). The populations of the leukocytes are gated as follows: total leukocytes, CD45⁺; neutrophils, CD11b⁺F4/80⁻Ly6G⁺; inflammatory monocyte, CD11b⁺F4/80⁻Ly6C⁺; macrophages, CD11b⁺F4/80⁺. The numbers (C) and percentages (D) of the leukocyte populations were analyzed on days 1, 3, and 5 after laser injury. Day 0 refers to a sample taken from uninjured eyes. n = 3–4 per group. (E) Immunofluorescence staining of the laser-injured RPE-choroids from WT mice (young, 8 weeks old; old, >20 weeks old) with anti-F4/80 (red) and -BLT1 (green) mAbs. Nuclei were visualized with DAPI (blue). LI (white dotted lines) denotes the location of laser injury. White arrows show F4/80⁻ and BLT1⁻ cells. White arrowheads show F4/80⁻ and BLT1⁻ double-positive cells. Scale bar: 100 μm (A) or 50 μm (E). (B) *P < 0.05 (Student's t test). (C and D) *P < 0.05; **P < 0.01; ***P < 0.005 versus Day 0 (1-way ANOVA with Dunnett’s post hoc test). Results are representative of at least 2 independent experiments.
BLT1 expression (Figure 5, A and B, and Supplemental Figure 6A, M0 and M1). Polarization of BMDMs was confirmed by examining the expression levels of mRNA for M2-specific markers including CD206 (Mrc1), CD301b (Mgl2), Arginase-1 (Arg1), Fizz1 (Retnla), and Ym1 (Chil3) (Supplemental Figure 6, B–G) or an M1 specific marker, iNOS (Nos2) (Supplemental Figure 6H). Consistent with these results, M2-polarization induced BLT1 expression in both RAW264.7 and THP-1 cells, and M1- or M0-polarization did not (Figure 5, C and D, left panels). Expression of PD-L2 and CD80 proteins also confirmed the proper M2 and M1 polarization, respectively (Figure 5, C and D, middle and right panels). In addition, we analyzed the number and percentage of M2 macrophages by FACS analysis (Figure 5, E–H). The absolute number of CD206+ M2 macrophages peaked at day 3 after laser injury (Figure 5E), but the percentage of CD206+ M2 macrophages in CD45+ total leukocytes (Figure 5F) or in CD11bhiF4/80hi total macrophages (Figure 5G) peaked at day 5 in the eyes of aged WT mice. The percentage of BLT1+CD206+ M2 macrophages was significantly higher during days 1–5 after laser injury (Figure 5E), but the percentage of CD206+ M2 macrophages in CD45+ total leukocytes (Figure 5F) or in CD11bhiF4/80hi total macrophages (Figure 5G) peaked at day 5 in the eyes of aged WT mice. The percentage of BLT1+CD206+ M2 macrophages was significantly higher during days 1–5 after laser injury in aged mice (Figure 5H). We also found that ocular-infiltrating BLT1+ macrophages expressed high levels of several M2 markers (CD206, CD301, and PD-L2) on day 5 after laser injury (Figure 5I). Interestingly, the expression levels of the M2 markers on BLT1+ macrophages were slightly higher than those on BLT1+ macrophages (Figure 5I, lower panels). To note, we found that BLT1 expression (Figure 5, J and K) in aged mice were higher than those in young mice in the ocular-infiltrating CD206+ M2 macrophages on day 3 after laser injury. These results suggest that the infiltration of ocular M2 macrophages is accelerated by age-dependent upregulation of BLT1.

The LTB₄-BLT1 axis upregulates recruitment of M2 macrophages and subsequent VEGF-A production. Although some molecules and signaling pathways have been implicated in the activation of M2 macrophages, the cellular and molecular mechanism is not fully elucidated. In general, BLT1 mediates LTB₄-induced calcium mobilization, chemotaxis, and inhibition of adenyl cyclase through the activation of Gq and Gi proteins (76). To determine whether M2 macrophages express functional BLT1 in vitro, we performed calcium mobilization (Figure 6A) and chemotaxis (Figure 6, B–D, and Supplemental Videos 1 and 2) assays. M2-polarized, but not M1- or M0-polarized, RAW264.7 cells exhibited increased intracellular calcium
Figure 5. M2-type macrophages express BLT1 and infiltrate into the injured eyes of aged mice. BMDMs from aged BLT1-WT (filled circles) and BLT1-KO (open circles) mice (>20 weeks old) were polarized to M1 and M2 macrophages, and BLT1 expression was examined by quantitative PCR (A) and flow cytometry analysis (B). M0 denotes a sample of nonpolarized BMDMs. RAW264.7 (C) and THP-1 (D) cells were polarized to M0 (cross plots), M1 (open squares), and M2 (filled circles) macrophages, and expression of BLT1, PD-L2 (an M2 marker), and CD80 (an M1 marker) was examined by flow cytometry. The y axis shows the MFI relative to that of an isotype control (mouse IgG1). MFI, mean fluorescence intensity. n = 3 per group. (E–H) FACS analysis of M2 macrophages isolated from the laser-injured eyes of aged WT mice (>20 weeks old) as described in Figure 3, C and D. CD206^+ M2 macrophages, CD11b^+ F4/80^+ CD206^+; CD206^+ BLT1^+ M2 macrophages, CD11b^+ F4/80^+ CD206^+ BLT1^+. n = 3–4 per group. (I) FACS analysis of M2 markers on the ocular-infiltrating BLT1^+ and BLT1^− macrophages on day 5 after laser injury from aged WT mice. CD206, CD301, and PD-L2 are specific surface markers of M2 macrophages. Cells were stained with anti-CD206, anti-CD301, and anti-PD-L2 mAbs (black outlines) or isotype controls (gray filled histograms). Overlays show the expression level of M2 markers on BLT1^+ (black outlines) and BLT1^− (black dotted lines) macrophages. These macrophages were gated as the CD45^+ F4/80^+ CD11b^+ population. (J and K) FACS analysis of BLT1 expression on the ocular-infiltrating CD206^+ M2 macrophages on day 3 after laser injury from young or aged WT mice. n = 3 per group. (A–I) **P < 0.01; ***P < 0.005; ****P < 0.001 versus 0 hours (2-way ANOVA with Bonferroni’s post hoc test). (E–H) *P < 0.05; **P < 0.01 versus day 0 (1-way ANOVA with Dunnett’s post hoc test). (K) **P < 0.01 (Student’s t test). Results are representative of at least 2 independent experiments (A–I).
mobilization upon LTB₄ stimulation (Figure 6A) and migrated along an increasing LTB₄ concentration gradient (Figure 6B and Supplemental Videos 1 and 2). The M2-RAW264.7 cells significantly responded to LTB₄ with a velocity and directionality of 3.29 unit s⁻¹ and 0.88, respectively (Figure 6, C and D). We next analyzed the expression levels of VEGF-A mRNA (Figure 7A) and protein (Figure 7B) in M2 BMDMs from BLT1-WT and BLT1-KO mice. Stimulation of LTB₄ significantly induced VEGF-A mRNA and protein expression in M2 BMDMs from BLT1-WT but not in BLT1-KO M2 BMDMs. Thus, LTB₄-BLT1 signal is important for activation of M2 macrophages.

**M2 macrophages promote BLT1-mediated development of CNV.** Recent findings have experimentally confirmed that adoptively transferred M2 macrophages develop CNV by stimulating an abnormal angiogenesis (52, 77–79). To clarify whether BLT1⁺ M2 macrophages exacerbate CNV, we adoptively transferred M0, M1, and M2 macrophages from BLT1-WT or BLT1-KO mice into laser-injured WT mice (Figure 8). Adoptive transfer of BLT1-WT M2-BMDMs resulted in marked CNV formation when compared with transfer of BLT1-KO M2-BMDMs (BLT1-WT M2 into WT, 10.5 × 10⁵ μm³; BLT1-KO M2 into WT, 4.4 × 10⁵ μm³); adoptive transfer of M0- and M1-BMDMs has little effect on CNV formation (BLT1-WT M0, 2.9 × 10⁵ μm³; BLT1-KO M0, 2.1 × 10⁵ μm³; BLT1-WT M1, 2.7 × 10⁵ μm³; BLT1-KO M1, 1.6 × 10⁵ μm³) (Figure 8, A and B). Histological analysis revealed that BLT1-WT M2-injected eyes developed more robust neovascularization in retinal and choroidal tissues than BLT1-KO M2-injected eyes (BLT1-WT M2 into WT, 2.8 × 10⁴ μm²; BLT1-KO M2 into WT, 1.0 × 10⁴ μm²) (Figure 8, C and D). Thus, expression of BLT1 is required for M2-induced CNV.

**Pharmacological inhibition of LTB₄-BLT1 signaling ameliorates CNV development.** Several studies demonstrated that a BLT1 antagonist CP1015696 completely blocked [³H]-labeled LTB₄ binding (IC₅₀ of 3.7 nM for human neutrophils) (80), calcium mobilization (0.1–1 μM for human neutrophils) (81), phagocytosis (1 μM for BMDMs) (82), and chemotaxis (0.1 μM for mouse peritoneal macrophages) (20) by antagonizing BLT1.
To investigate whether blockade of LTB4-BLT1 signaling (Supplemental Figure 1) (9, 83, 84) attenuates CNV, we treated mice by IVI of CP105696, prior to laser-induced injury (Figure 9, A and C, upper panels). We also tested the effects of 3 inhibitors of LTB4-producing enzymes: zileuton, a specific inhibitor of 5-LO; MK-886, a specific inhibitor of FLAP; and bestatin, an inhibitor of LTA4H (Figure 9A, lower panels, and Figure 9C, middle and lower panels). CP105696 caused a dose-dependent reduction in CNV volume (DMSO, 6.6 × 10^5 μm^3; CP105696, 0.2 pmol [3.5 × 10^5 μm^3], 2 pmol [2.0 × 10^5 μm^3], 20 pmol [1.0 × 10^5 μm^3]) (Figure 9B) and in CNV lesion area (DMSO, 3.5 × 10^4 μm^2; CP105696, 20 pmol [1.6 × 10^4 μm^2]) (Figure 9D). The CNV development was also inhibited by treatment with zileuton, MK-886, or bestatin (CNV volume: zileuton, 2.8 × 10^5 μm^3; MK-886, 2.8 × 10^5 μm^3; bestatin, 1.9 × 10^5 μm^3) (CNV lesion area: zileuton, 1.3 × 10^4 μm^2; MK-886, 1.8 × 10^4 μm^2; bestatin, 1.4 × 10^4 μm^2) (Figure 9, B and D). Moreover, we confirmed that CP105696 suppressed the infiltration of CD206+ M2 macrophages and BLT1+CD206+ M2 macrophages (Figure 9, E and F).

Given that some of these drugs are orally available, the LTB4-BLT1 axis may become a novel therapeutic target for laser-induced CNV.

**Discussion**

Here, we demonstrate that the volume of CNV in BLT1-WT mice, but not in BLT1-KO mice, increased in an age-dependent manner (Figure 1). A high-affinity LTB4 receptor, BLT1, which was expressed in ocular-infiltrating macrophages (Figure 3E) was responsible for CNV (Figure 4 and 8). On the other hands, a low-affinity LTB4 receptor, BLT2, which is ubiquitously expressed in human and mouse tissues (85) including cornea and conjunctiva (86), was not involved in laser injury-induced CNV because there was no significant difference in CNV volume and histology between BLT2-WT and BLT2-KO mice (Supplemental Figure 2). As we reported recently, M2-type macrophages are important for the development of CNV after laser injury (53); here, we also demonstrate that ocular-infiltrating M2 macrophages contributed to CNV development via LTB4-BLT1 signaling pathway. Indeed, laser-induced injury increased the amount of LTB4 in the eyes (Figure 2B), which then attracted BLT1+ M2 macrophages to the injured mouse retina (Figure 5, E–K). We also found that BLT1 was only induced during M2 polarization of primary mouse macrophages (Figure 5, A and B) and mouse (Figure 5C) or human (Figure 5D) macrophage cell lines. Preliminary experiments with a STAT3 selective inhibitor suggest that, of these, the IL-10/JAK1/STAT3 signaling pathway is likely critical for induction of BLT1 expression (Supplemental Figure 7). Recent studies show that expression of IL-10 and M2 markers (e.g., CD163 and Arginase-1), but not M1 markers (e.g., IL-6 and TNF-α), is increased in senescent macrophages, thereby promoting CNV development (51, 52). Therefore, we expected that BLT1 expression is also increased in senescent M2 macrophages in the eyes of older mice.

We actually found that the BLT1 expression of M2 macrophages in the older eyes was higher than that in the younger eyes after induction of laser injury (Figure 5, J and K). The elevated BLT1 could accelerate LTB4-dependent recruitment of M2 macrophages to CNV lesions, leading to the production of various...
proangiogenic factors, including VEGF-A through the activation of BLT1 (Figure 7). Such chain of events would also promote human CNV in wet AMD.

The findings presented herein might contribute to the development of novel anti-AMD drugs (Figure 9). Although anti-VEGF agents (e.g., ranibizumab and bevacizumab) are clinically and commercially available for wet AMD (87), several clinical trials have examined new therapeutic agents that targeting components of the VEGF (e.g., VEGF receptor tyrosine kinases) or other signaling pathways (e.g., PDGF) (88). To date, the LTB$_4$-BLT1 axis has not been examined in AMD. We speculate that agents that target the LTB$_4$-BLT1 axis might become useful treatment options for human patients with severe wet AMD. In fact, we examined the BLT1 expression in the diabetic human donor eyes (early progressive diabetic retinopathy, age 55, female) compared with nondiabetic human donor eyes (car accident, age 13, male) (data not shown). We found that BLT1+ cells infiltrated into the periphery of the macular drusen, a common early sign of AMD, and choroidal capillaries in the RPE-choroid of diabetic human eyes but not in nondiabetic human eyes. Recent studies show that infiltrated macrophages exhibit M2-phenotype, which accelerate neovascularization to promote tissue repair in the injured retina (38, 79, 89, 90). Hence, the BLT1 may be a promising therapeutic target for CNV of several diseases, including wet AMD. The 5-LO inhibitor zileuton is clinically used as an antiasthmatic drug worldwide (83), and the LTA$_4$H inhibitor Ubenimex (bestatin) is a chemotherapy agent in Japan (84), with known safety profiles in both cases. This allows their potential off-label use as therapeutic agents for wet AMD, thereby ensuring patient safety. In contrast, MK-886 and CP105696 are not used clinically; thus, more effective and safe inhibitors of FLAP, and antagonists of BLT1, are required.

**Figure 8. M2 macrophage-dependent CNV development requires BLT1.** Images of iB$_4$ staining (A) and CNV volume (B) in the RPE-choroid of recipient mice that received M0-, M2-, and M1-BMDMs from aged BLT1-WT (open circles) or BLT1-KO (filled circles) mice (>20 weeks old). n = 6–8 mice per group. (C and D) H&E staining of the laser-injured retinas of recipient mice receiving M2-BMDMs from BLT1-WT or BLT1-KO mice (>20 weeks old). Yellow dotted lines show the lesion area. n = 4 per group. Scale bar: 100 μm (A and C). (B and D) *P < 0.05 (1-way ANOVA with Bonferroni’s post hoc test [B] and Student’s t test [D]). Results are representative of at least 2 independent experiments.
In conclusion, LTB₄ was found to be a key mediator that attracted M2 macrophages to the laser-injured retinas via BLT₁, thereby increasing the severity of CNV. Antagonists of BLT₁ or inhibitors of LTB₄ biosynthesis may become novel therapeutic agents to inhibit CNV of wet AMD.

Figure 9. The effects of a BLT₁ antagonist and LTB₄ synthesis inhibitors on development of CNV. Images of iB₄ staining (A) and CNV volume (B) in the RPE-choroid from aged WT mice (>20 weeks old) after administration of 0.2–20 pmol of CP105696 (a BLT₁ antagonist; filled circles) or 20 pmol of zileuton (a 5-LO inhibitor), MK-886 (a FLAP inhibitor), or bestatin (a LTA₄H inhibitor) (filled triangles), or vehicle (open circles). n = 4–9 mice per group. (C and D) Images of H&E staining (C) and CNV lesion area (D). H&E staining of the retinas after aged WT mice (>20 weeks old) with laser-induced injury were treated with CP105696, zileuton, MK-886, and bestatin (20 pmol/eye) or DMSO. Yellow dotted lines show the lesion area. n = 3–6 per group. (E and F) The number of the ocular-infiltrating CD206⁺ or CD206⁺BLT₁⁺ M2 macrophages was analyzed on day 3 after laser injury from CP105696- (20 pmol/eye) or DMSO-injected WT mice (>20 weeks old). n = 3–4 per group. Scale bar: 100 μm (A and C). *P < 0.05; **P < 0.01 (1-way ANOVA with Dunnett’s post hoc test [B and D] and Student’s t test [E and F]). Results are representative of at least 2 independent experiments (A–D).
Methods

Animals. BLT1-KO and BLT2-KO mice were generated as previously described (13, 64) and then backcrossed with C57BL/6J mice for more than 12 generations. Aged WT mice (C57BL/6J > 20 weeks old) were purchased from Japan SLC or Kyudo. All mice were maintained in a filtered-air laminar-flow enclosure in a specific pathogen-free facility and given standard laboratory food and water.

Reagents. The selective BLT1 antagonist, CP105696, was from Pfizer. zileuton (a 5-LO inhibitor), MK-886 sodium salt hydrate (a FLAP inhibitor), and bestatin hydrochloride (an inhibitor of aminopeptidases, including LTA₄H) were obtained from MilliporeSigma. LTB₄ was purchased from Cayman Chemical. Unless otherwise noted, all Abs and cytokines were purchased from BioLegend and PeproTech, respectively.

Laser-induced wet AMD model. Mice were anesthetized by i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), and the pupils were dilated by application of 0.2% tropicamide and 1% phenylephrine hydrochloride (Santen Pharmaceutical Co.). Using a 532-nm laser, a slit-lamp delivery system, and a slide glass as a contact lens, 4 spots (laser power, 200 mW; exposure time, 100 ms; hole size, 75 µm) were placed in each eye. After laser-induced injury and prior to administration of antagonists/inhibitors, the eyes were subjected to IVI of CP105696 (0.2–20 pmol), zileuton (20 pmol), MK-886 (20 pmol), bestatin (20 pmol), or DMSO (vehicle, 0.1%). The volume of the CNV lesions was measured in choroidal flat mounts on day 7 after injury. The anterior segment and retina were removed from the eyecup after fixation in 4% paraformaldehyde in PBS (Wako). The remaining RPE-choroid complex was dehydrated in methanol and stained with 7 µg/ml fluorescein-labeled iB4 (derived from Griffonia Simplicifolia Lectin I) (Vector Laboratories). After relaxing radial incisions, this complex was flat mounted using mounting medium (Thermo Fisher Scientific) and coverslips. Z-stack images were obtained using a confocal microscope (A1R+; Nikon), and the CNV volume was analyzed on reconstructed 3-dimensional images using NIS-Elements (Nikon).

Polarization of M1 and M2 macrophages. BM cells in the femur and tibia were collected from BLT1-WT and BLT1-KO mice (>20 weeks old) and further differentiated in RPMI 1640 (Wako) supplemented with 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin (P/S) (Nacalai) into BMDMs by treatment with 50 ng/ml M-CSF for 3 days. RAW264.7 (a subclone from clone TIB-71) (ATCC) and THP-1 (clone TIB-202) (ATCC) cell lines were maintained in RPMI 1640 supplemented with 10% FCS and P/S. BMDMs and RAW264.7 cells were polarized by exposure to 2 ng/ml mouse IFN-γ and 0.1 µg/ml LPS (MilliporeSigma) (M1) or 20 ng/ml IL-4, IL-10, and IL-13 (from mouse) and 2 ng/ml human TGF-β1 (R&D Systems) (M2) during 48 hours. THP-1 cells were stimulated with 150 nM PMA for 24 hours and then polarized with 2 ng/ml human IFN-γ and 0.1 µg/ml LPS (M1) or 20 ng/ml IL-4, IL-10, and IL-13 (from human) and 2 ng/ml human TGF-β1 (M2) during 48 hours. M0 macrophages were generated by culture in medium without cytokines. All cells were cultured under standard conditions at 37°C and 5% CO₂ in a humidified atmosphere.

H&E staining. Eyes were removed, soaked in 10% buffered formalin solution, embedded in paraffin, sliced (10-µm thickness) using a microtome, and stained with H&E. Images were acquired under a light microscope (BZ-9000; Keyence) and quantified the CNV lesion area using Image J (NIH).

Quantitative PCR (qPCR). Eyecups (the remaining retina, choroid, and RPE from 1–2 eyes) and M0-, M1-, or M2-polarized BMDMs were prepared from BLT1-WT and BLT1-KO mice. For VEGF-A mRNA expression analysis, M2 BMDMs were stimulated with 500 nM LTB₄ or ethanol (as a vehicle control) for 0.5 hours. All samples were treated with TRIzol reagent (Thermo Fisher Scientific) to isolate RNA, according to the manufacturer’s instructions. cDNA was synthesized from total RNA with reverse transcriptase and an optimized blend of oligo-dTs and random primers using an QuantiTect Reverse Transcription kit (Qiagen) or qPCR RT Master Mix (Toyobo). Target genes were amplified using a real-time PCR System (Thermo Fisher Scientific), DNA polymerase, SYBR Green I Dye (Thermo Fisher Scientific), and specific primers. Gene expression was normalized to 18S rRNA (Rn18s) using the ΔΔCT method. The sequences of the primers are as follows: Vgf4: forward, 5′-acttgacccctgatcttg-3′, and reverse, 5′-ctctggctctgtgtgg-3′; Rn18s: forward, 5′-gcataattttccatatagcc-3′, and reverse, 5′-ggaggtaaatcagccag-3′; Pdgfb: forward, 5′-cgcgctgtgactaagatacc-3′, and reverse, 5′-gagctgggacctgtttc-3′; Fgf2: forward, 5′-cggctctgctggctgttaac-3′, and reverse, 5′-gtgctggcttgatgtggg-3′; Il1b: forward, 5′-gttaagaaagacgagcaacc-3′, and reverse, 5′-tcctttggggttacctttc-3′; Tnf: forward, 5′-ttctttcattcgtttgctttgg-3′, and reverse, 5′-gggctgctgctgctgctgctgctg-3′; Tgfb1: forward, 5′-taggacatccatgacggcaact-3′, and reverse, 5′-aaagagaagactctgcaagcta-3′.
LTD4, were then incubated with mouse Fc blocker, followed by staining with anti–CD45-FITC (2.5 μg/ml). Cells were isolated using Collagenase D (Roche Diagnostics) in RPMI 1640 as previously described (94). Cells were collected from 4–6 laser-injured eyes as follows: (a) young (8- to 12-week-old) or aged (>20-week-old) WT mice or (b) CP105696- (20 pmol/eye) and DMSO-injected WT mice (> 20 weeks old), and ocular-infiltrating cells were stained with anti–human BLT1 (diluted 1:20; clone 203/14F11) (R & D Systems), anti-CD80 (10 μg/ml; clone 16-10A1), or isotype controls for biotin-labeled anti-mouse Abs (eBioscience). After washing with PBS/2 mM EDTA, cells were stained with R-phycoerythrin–conjugated (PE-conjugated) Streptavidin (0.5 μg/ml; eBioscience). THP-1 cells were collected in FACS buffer, blocked with human Fc blocker (Miltenyi Biotec) and stained with anti–human BLT1 (diluted 1:20), anti-CD80 (10 μg/ml; clone 16-10A1), or isotype controls for PE-labeled anti-human Abs (eBioscience). Nuclei were stained with DAPI (5 μg/ml; MilliporeSigma). Samples were visualized under a confocal microscope (AIR™; Nikon).

Flow cytometry analysis. BMDMs and RAW264.7 cells were collected in PBS/2 mM EDTA (pH 7.4) containing 2% FCS (FACS buffer). Fc receptors were then blocked with an anti-CD16/32 (5 μg/ml; 2.4G2) Ab (Fc blocker). BMDMs were stained with anti-F4/80-80-FTTC (5 μg/ml; clone BM8), anti-CD11b-allophycocyanin (APC) (2.5 μg/ml; clone M1/70), and biotin-labeled anti–mouse BLT1 (5 μg/ml; clone 7A8; generated in-house) Ab (93) or mouse IgG, (5 μg/ml; ebioscience) (as an isotype control). RAW264.7 cells were stained with anti–mouse BLT1 (5 μg/ml; clone 7A8), anti–PD-L2 (2.5 μg/ml; clone TY25), anti–CD80 (2.5 μg/ml; clone 16-10A1), or isotype controls for biotin-labeled anti-mouse Abs (ebioscience). After washing with PBS/EDTA, cells were stained with R-phycocerythrin–conjugated (PE-conjugated) Streptavidin (0.5 μg/ml; ebioscience). THP-1 cells were collected in FACS buffer, blocked with human Fc blocker (Miltenyi Biotec) and stained with anti–human BLT1 (diluted 1:20; clone 203/14F11) (R&D Systems), anti–PD-L2 (5 μg/ml; clone 24F10C12), anti–CD80 (10 μg/ml; clone 2D10), or an isotype control for PE-labeled anti-human Abs (Bio-Legend). Cells were analyzed in a flow cytometer (FACSCalibur or LSRFortessa; Becton Dickinson). Eyecups were collected from 4–6 laser-injured eyes as follows: (a) young (8- to 12-week-old) or aged (>20-week-old) WT mice or (b) CP105696- (20 pmol/eye) and DMSO-injected WT mice (> 20 weeks old), and ocular-infiltrating cells were isolated using Collagenase D (Roche Diagnostics) in RPMI 1640 as previously described (94). Cells were then incubated with mouse Fc blocker, followed by staining with anti–CD45-FTTC (2.5 μg/ml; clone 13.12 software package (Thermo Fisher Scientific).
30-F11; Becton Dickinson), anti–Ly6G-PE/Cy7 (2.5 µg/ml; clone 1A8), anti–Ly6C-APC/Cy7 (2.5 µg/ml; clone HK1.4), anti–F4/80-Brilliant Violet 421 (2.5 µg/ml; clone BM8), anti–CD11b-Brilliant Violet 510 (5 µg/ml; clone M1/70), and anti–mouse BLT1-APC (5 µg/ml; clone 7A8; generated in-house) Abs in addition to 2.5 µg/ml anti–PD-L2 (clone TY25; BioLegend), 10 µg/ml anti-CD301 (clone ER-MP23; Bio-Rad), 10 µg/ml anti-CD206 (clone MR5D3; BioLegend) biotin-conjugated Abs or isotype controls. Cells were washed and stained with 0.5 µg/ml Streptavidin-PE and were analyzed in a flow cytometer (FACSVerse; Becton Dickinson). For all experiments, dead cells were excluded after staining with 7AAD (Becton Dickinson).

**Liposome-mediated depletion of macrophages.** Aged BLT1-WT and BLT1-KO mice (>20 weeks old) received an IVI of 90 µg clodronate liposomes (including 16 µg of clodronic acid; injection volume, 2 µl/eye) (Katayama Chemical Industries) or control liposomes after laser-induced injury. RPE-choroid complexes were prepared as described above, stained with Alexa 647–labeled anti-F4/80 mAb or rat IgG2a (as an isotype control), and then nuclei were visualized with DAPI. F4/80+ macrophages and DAPI+ cells per field were counted using ImageJ.

**Adoptive transfer of macrophages.** Aged WT mice received M0, M1, and M2 BMDMs (1 × 10^5 cells in PBS/eye; injection volume, 2 µl/eye) from aged BLT1-WT or BLT1-KO mice (>20 weeks old) via IVI after laser-induced injury.

**Calcium mobilization assay.** RA W264.7 cells were incubated for 60 minutes with HBSS-based loading buffer containing 20 mM HEPES (pH 7.4) (Thermo Fisher Scientific), 2.5 mM Probenecid (MilliporeSigma), 0.04% Pluronic F-127 (Thermo Fisher Scientific), and 4 µM Fluo 4-AM (Dojindo laboratories). Cells were then washed with HEPES-based buffer, seeded into 96-well black plates (1 × 10^4 cells/well), and stimulated with 0.5–1,000 nM LTB4 or 2 µM Ionomycin (MilliporeSigma). Assay plates were then analyzed using FlexStation 3 (Molecular Devices).

**TAXIScan chemotaxis assay.** Chemotaxis of RAW264.7 cells toward 100 nM LTB4 or ethanol (as a vehicle control) was monitored using TAXIScan-FL (Effector Cell Institute Frontier), as described previously (95). Phase-contrast sequential images were acquired at 1-minute intervals for 45 minutes and stacked using ImageJ. Chemotactic parameters (velocity and directionality) were analyzed with the ImageJ Manual Tracking plug-in and the ImageJ Chemotaxis and Migration tools plug-in.

**ELISA.** For VEGF-A protein expression analysis, culture media were collected in M2 BMDMs from BLT1-WT or BLT1-KO mice after stimulation with 500 nM LTB4 or ethanol (as a vehicle control) for 4 hours. VEGF-A was measured culture media using the Mouse VEGF Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions.

**Statistics.** Data are expressed as the mean ± SEM of at least 3 independent mice or eyes. Two data sets were compared using 2-tailed Student’s t test. Multiple comparisons were performed using 1-way ANOVA followed by Bonferroni’s, Newman-Keuls, or Dunnett’s post hoc test, and 2-way ANOVA followed by Bonferroni’s post hoc test. P value of less than 0.05 was considered statistically significant. All statistical analyses were performed using Prism version 5.0 (GraphPad Software).

**Study approval.** All animal studies and procedures were approved by the Ethics Committees on Animal Experimentation in Juntendo University (approval nos. 250224, 260166, 270161, 280167, and 290171). All the studies in this manuscript were carried out in accordance with approved guidelines and regulations.

**Author contributions**

FS and TY designed all experiments. FS, MO, KI, HA, and MRK performed the experiments. TK, MO, KS, TO, KJ, TN, SN, SY, TI, HA, MRK, AHM, JMP, KHS, and TY helped acquire and analyze data. TY performed experiments. FS, AHM, and TY wrote the manuscript.

**Acknowledgments**

This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japan Society for the Promotion of Science (JSPS) (grant nos. 22116001, 22116002, 15H05897, 15H05904, 15H04708, and 18H02627 to TY; 25860223, 15K19032, and 17K08664 to TK; 24590386, 15K08316, and 18K06923 to K; and 25460374, 16K08596, and 15KK0320 to TO) and by grants from the Naito Foundation, the Ono Medical Research Foundation, the Uehara Memorial Foundation, the Mitsubishi Foundation, and the Takeda Science Foundation. This study was supported in part by a Grant-in-Aid (S1311011 to TY) from the Foundation for Strategic Research Projects in Private Universities of the MEXT and by a grant from the Institute for Environmental and Gender-Specific
Medicine. We thank the Research Center for Human Disease Modeling (Kyushu University), the Research Support Center of the Division of Molecular and Biochemical Research (Juntendo University), and the Imaging Core Laboratory of the Institute of Medical Science (The University of Tokyo) for technical support. We also thank Eiichi Hasegawa (Harvard Medical School, Boston, Massachusetts, USA) and Akihiko Yoshimura (Keio University, Tokyo, Japan) for technical support of AMD model and BM transplantation, Takako Ichiki (California Institute of Technology, Pasadena, California, USA) for technical support of chemotaxis assay, and Miki Honda (Juntendo University), Akira Matsuda (Juntendo University), and the members of our laboratory for advice and helpful discussion.

Address correspondence to: Takehiko Yokomizo, Department of Biochemistry, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 81.3.5802.1030; Email: yokomizo-tyk@umin.ac.jp.

TK’s present address is: Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.

FS’s present address is: Department of Cell Signaling, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.


